CATABASIS PHARMACEUTICALS IN's ticker is and the CUSIP is 14875P206. A total of 64 filers reported holding CATABASIS PHARMACEUTICALS IN in Q4 2020. The put-call ratio across all filers is 0.59 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $34,000 | +21.4% | 11,801 | -9.5% | 0.00% | – |
| Q4 2020 | $28,000 | -50.9% | 13,044 | +42.3% | 0.00% | – |
| Q3 2020 | $57,000 | +7.5% | 9,167 | +10.4% | 0.00% | – |
| Q2 2020 | $53,000 | +71.0% | 8,305 | +55.7% | 0.00% | – |
| Q4 2019 | $31,000 | -85.4% | 5,333 | -80.2% | 0.00% | – |
| Q1 2019 | $213,000 | -45.5% | 26,906 | -70.0% | 0.00% | – |
| Q4 2018 | $391,000 | – | 89,682 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eversept Partners, LP | 522,042 | $1,117,170 | 0.13% |
| XTX MARKETS LLC | 26,041 | $56,000 | 0.12% |
| Samsara BioCapital, LLC | 300,000 | $642,000 | 0.06% |
| Ikarian Capital, LLC | 650,000 | $1,392,000 | 0.06% |
| Opaleye Management Inc. | 187,750 | $402,000 | 0.05% |
| SABBY MANAGEMENT, LLC | 108,026 | $231,000 | 0.04% |
| Anson Funds Management LP | 97,601 | $209,000 | 0.04% |
| Virtu Financial LLC | 83,221 | $178,000 | 0.02% |
| GSA CAPITAL PARTNERS LLP | 47,084 | $101,000 | 0.02% |
| WEXFORD CAPITAL LP | 19,512 | $42,000 | 0.01% |